polypeptide N-acetylgalactosaminyltransferase like 5Genealiases: GALNACT19 · GALNT15 · GalNAc-T5L
Q-omics provides the consensus-scored GALNTL5 profile across patient tissues and cancer cell-line models. GALNTL5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GALNTL5 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, GALNTL5 RNA expression shows 9,678 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where GALNTL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNTL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNTL5 survival associations across molecular data types. GALNTL5 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNTL5 RNA expression–survival associations across cancer types. High GALNTL5 expression shows unfavorable associations in KIRC, ACC, THCA, LIHC, THYM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GALNTL5 RNA expression.
This table summarizes GALNTL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GALNTL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNTL5 shows lower tumor expression in KICH and higher tumor expression in KIRC, UCEC, KIRP, HNSC and LUAD. The KIRC box plot shows higher GALNTL5 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p < 0.001).
This table shows molecular features associated with GALNTL5 in patient tissues and cancer cell lines. In patient samples, GALNTL5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNTL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OVARY.
